公开(公告)号：US20230131025A1

公开(公告)日：2023-04-27

申请号：US17799234

申请日：2021-02-08

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiangyong LIU ,  Changyong QIU ,  Mengqiang LIU ,  Xiaodong SONG ,  Qichao SHEN ,  Guolong DU ,  Haitong SHENG ,  Lieming DING ,  Jiabing WANG

IPC: C07D401/12 ,  C07D215/38 ,  A61P35/00 ,  C07D401/14 ,  C07D417/14

Abstract: The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.

公开(公告)号：US20220064196A1

公开(公告)日：2022-03-03

申请号：US17422700

申请日：2020-01-14

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiangyong LIU ,  Jiabing WANG ,  Lieming DING

IPC: C07F9/6561

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20240352053A1

公开(公告)日：2024-10-24

申请号：US18683571

申请日：2022-08-19

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Liang CHEN ,  Changyong QIU ,  Xiangyong LIU ,  Jian TANG ,  Lieming DING ,  Jiabing WANG

IPC: C07F9/6558 ,  A61K31/675 ,  C07C55/10 ,  C07C57/15 ,  C07C59/245 ,  C07C59/255 ,  C07C309/04

CPC classification number: C07F9/65583 ,  A61K31/675 ,  C07C55/10 ,  C07C57/15 ,  C07C59/245 ,  C07C59/255 ,  C07C309/04 ,  C07B2200/13

Abstract: The present invention relates to salt and crystal form of an EGFR inhibitor, and a composition and the use thereof. The salt and crystal form of the EGFR inhibitor as represented by formula I of the present invention can be used for treating or preventing epidermal growth factor receptor-mediated diseases or medical conditions (such as L858R activation mutants, exon 19 deletion activation mutants, T790M resistance mutants and C797S resistant mutants) in certain mutant forms.

公开(公告)号：US20220402948A1

公开(公告)日：2022-12-22

申请号：US17763633

申请日：2020-09-25

Applicant: BETTA PHARMACEUTICALS CO., LTD.

Inventor： Xiangyong LIU ,  Changyong QIU ,  Haitong SHENG ,  Mengqiang LIU ,  Qichao SHEN ,  Guolong DU ,  Xiaodong SONG ,  Lieming DING ,  Jiabing WANG

IPC: C07F9/53

Abstract: The present invention relates to the compounds of Formula I, methods of using these compounds as EGFR inhibitors, and pharmaceutical compositions comprising compounds thereof. The compounds are used for treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20220119411A1

公开(公告)日：2022-04-21

申请号：US17259187

申请日：2019-07-12

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Bang FU ,  Yao ZHANG ,  Yiqian WANG ,  Xiangyong LIU ,  Jiabing WANG ,  Lieming DING

IPC: C07D513/04 ,  C07D471/04 ,  C07D498/04 ,  C07D519/00 ,  C07D487/04 ,  C07D417/14

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20230391779A1

公开(公告)日：2023-12-07

申请号：US18021784

申请日：2021-08-17

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiaofeng XU ,  Jinheng GAO ,  Hongfei RONG ,  Xizhen SONG ,  Jie CHEN ,  Xiangyong LIU ,  Hongling SHEN ,  Jing GUO ,  Dan YAN ,  Hong LAN ,  Lieming DING ,  Jiabing WANG

IPC: C07D487/04 ,  C07D403/04 ,  C07D471/04 ,  C07D403/06 ,  C07D231/56 ,  C07D401/14 ,  C07D401/04 ,  C07D405/04 ,  C07D413/04 ,  C07D413/14 ,  C07D405/14 ,  C07D493/04 ,  C07C237/20 ,  C07D205/04 ,  A61P35/00

CPC classification number: C07D487/04 ,  A61P35/00 ,  C07D471/04 ,  C07D403/06 ,  C07D231/56 ,  C07D401/14 ,  C07D401/04 ,  C07D405/04 ,  C07D413/04 ,  C07D413/14 ,  C07D405/14 ,  C07D493/04 ,  C07C237/20 ,  C07D205/04 ,  C07D403/04

Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions comprising such compounds and use thereof. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer.

公开(公告)号：US20230053342A1

公开(公告)日：2023-02-23

申请号：US17773771

申请日：2020-11-04

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Houxian ZU ,  Xizhen SONG ,  Kai CHEN ,  Xiangyong LIU ,  Jie CHEN ,  Yajing BIAN ,  Lieming DING ,  Jiabing WANG

IPC: C07D498/04 ,  C07D513/04 ,  A61P35/00

Abstract: An imidazolidinone compound represented by formula (I), or a stereoisomer thereof, a geometric isomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, a synthesis method therefor and use thereof.

公开(公告)号：US20220227796A1

公开(公告)日：2022-07-21

申请号：US17439324

申请日：2020-03-31

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiangyong LIU ,  Changyong QIU ,  Qichao SHEN ,  Mengqiang LIU ,  Haitong SHENG ,  Guolong DU ,  Jiabing WANG ,  Lieming DING

IPC: C07F9/6512 ,  C07F9/6561 ,  A61P35/00

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20220162214A1

公开(公告)日：2022-05-26

申请号：US17594104

申请日：2020-04-01

Applicant: Meryx, Inc. ,  The University of North Carolina at Chapel Hill ,  Betta Pharmaceuticals Co., Ltd.

Inventor： Xiaodong WANG ,  Weihe ZHANG ,  Xiangyong LIU ,  Changlong HAN ,  Zongquan LI

IPC: C07D487/04 ,  A61K45/06 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02

Abstract: The invention relates to new crystal forms of compound (trans)-4-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl) cyclohexanol trihydrochloride, its hydrate, or solvate, as shown in Formula I. The invention also relates to methods for preparation of the described compound, crystal form, and related intermediate compounds, as well as pharmaceutical compositions containing the compounds. Further described is, the use of the compounds or crystal forms in the production of a medicament for the treatment of a disease, symptom, or condition, or the use in treatment of a disease, symptom or condition.

公开(公告)号：US20210395256A1

公开(公告)日：2021-12-23

申请号：US17311105

申请日：2019-12-06

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Bang FU ,  Yinlong LI ,  Wei REN ,  Jie CHEN ,  Xiangyong LIU ,  Jiabing WANG ,  Lieming DING

IPC: C07D487/04 ,  C07D519/00

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as Trk inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.